Аннотация
Аутоиммунные буллезные дерматозы представляют собой гетерогенную группу редких заболеваний кожи и слизистых
оболочек, характеризующихся продукцией аутоантител, нацеленных на структурные белки эпителиальной ткани и под-
лежащей базальной мембраны. Появившиеся на рынке за последние два десятилетия высокочувствительные и специфичные
тест-системы для иммуноферментного анализа на основе рекомбинантных форм целевых антигенов предоставили новый
эффективный инструмент для диагностики ряда аутоиммунных буллезных дерматозов. Цель данной статьи – обобщить
информацию о современных наборах для ИФА диагностики буллезных дерматозов. В обзоре описаны диагностические воз-
можности, шкала оценки результата и особенности постановки иммуноферментного анализа для представленных тест-
систем. Кроме того, приведена информация о разработке аналогичных диагностических инструментов в Российской Феде-
рации.
Annotation
Autoimmune bullous dermatoses are a heterogeneous group of rare diseases of the skin and mucous membranes characterized by the
production of autoantibodies targeting structural proteins of epithelial tissue and the underlying basal membrane. Highly sensitive
and specific immunoassay test systems based on recombinant forms of target antigens that have appeared on the market in the last
two decades have provided a new effective tool for the diagnosis of a number of autoimmune bullous dermatoses. The purpose of this
article is to summarize information on current ELISA kits for the diagnosis of bullous dermatoses. The review describes the diagnostic
capabilities, the result evaluation scale and the specifics of immunoassay staging for the test systems. In addition, information on the
development of similar diagnostic tools in the Russian Federation is given.
Key words: review; recombinant proteins; autoimmune bullous dermatoses; enzyme immunoassay
Список литературы
Л И Т Е РАТ У РА ( П П . 1 — 4 4 , 4 7 СМ.
R E F E R E NC E S )
45. Свирщевская, Е.В., Матушевская Е.В., Дзуцева И.Р., Лысенко А.А.
Разработка иммуноферментной тест-системы на основе дрожже-
вого рекомбинантного десмоглеина 3 для серодиагностики вуль-
гарной пузырчатки. Вестник дерматологии и венерологии, 2005;
(3): 4-10.
46. Матушевская Е.В., Свирщевская Е.В., Дзуцева И.Р., Тогоева Л.Т.,
Лапшина Т.П. Изменение уровня антител к десмоглеину-3 в сыво-
ротках крови больных пузырчаткой до и после лечения. Вестник
дерматологии и венерологии, 2005; (6): 12-6.
R E F E R E NC E S
1. Egami S., Yamagami J., Amagai M. Autoimmune bullous skin diseases,
pemphigus and pemphigoid. J. Allergy Clin. Immunol. 2020; 145:
1031–47. DOI: 10.1016/j.jaci.2020.02.013.
2. Bystryn J.C., Steinman N.M. The adjuvant therapy of pemphigus. An
update. Arch. Dermatol. 1996; 132 (2): 203–12. DOI: 10.1001/archderm.
1996.03890260105016.
3. Hegazy M., Perl A.L., Svoboda S.A., Green K.J. Desmosomal cadherins
in health and disease. Annu. Rev. Pathol. Mech. Dis. 2022; 17:
47-72. DOI: 10.1146/annurev-pathol-042320-092912.
4. Saschenbrecker S., Karl I., Komorowski L., Probst C., Dähnrich
C., Fechner K. et al. Serological diagnosis of autoimmune bullous
skin diseases. Front. Immunol. 2019; 10: 1–18. DOI: 10.3389/fimmu.
2019.01974.
5. Schmidt E., Kasperkiewicz M., Joly P. Pemphigus. Lancet. 2019; 394:
882–94. DOI: 10.1016/S0140-6736(19)31778-7.
6. Harrison O.J., Brasch J., Lasso G., Katsamba P.S., Ahlsen G., Honig B.
et al. Structural basis of adhesive binding by desmocollins and desmogleins.
Proc. Natl. Acad. Sci .USA 2016; 113: 7160–5. DOI: 10.1073/
pnas.1606272113.
7. van Beek N., Zillikens D., Schmidt E. Diagnosis of autoimmune bullous
diseases. J. Dtsch. Dermatol. Ges. 2018; 16(9): 1077–91. DOI:
10.1111/ddg.13637.
8. Kasperkiewicz M., Ellebrecht C.T., Takahashi H., Yamagami J., Zillikens
D., Payne A.S. et al. Pemphigus. Nat. Rev. Dis. Primers 2017; (3):
17026. DOI: 10.1038/nrdp.2017.26.
9. Fujioa Y., Kojimab К., Hashiguchib М., Wakui M., Murata M., Amagai
M. et al. Validation of chemiluminescent enzyme immunoassay in
detection of autoantibodies in pemphigus and pemphigoid. Journal of
Dermatological Science. 2017; 85 (3): 208-15. DOI: 10.1016/j.jdermsci.
2016.12.007.
10. Futei Y., Amagai M., Sekiguchi M., Nishifuji K., Fujii Y., Nishikawa
T. Use of domain-swapped molecules for conformational epitope
mapping of desmoglein 3 in pemphigus vulgaris. J. Invest. Dermatol.
2000; 115 (5): 829-834. DOI: 10.1046/j.1523-1747.2000. 00137.x.
11. Schmidt E., Dähnrich C., Rosemann A., Probst C., Komorowski L.,
Saschenbrecker S. et al. Novel ELISA systems for antibodies to desmoglein
1 and 3: correlation of disease activity with serum autoantibody
levels in individual pemphigus patients. Exp. Dermatol. 2010; 9 (5):
458–63. DOI: 10.1111/j.1600-0625.2010.01069.x.
12. Yang A., Xuan R., Melbourne W., Tran K., Murrell D.F. Validation of
the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus
vulgaris and pemphigus foliaceus. J. Eur. Acad. Dermatology Venereol.
2020; 34 (1): 153–60. DOI: 10.1684/ejd.2015.2692.
13. Human anti-DSG3 antibody (anti-desmoglein-3 antibody) ELISA kit.
Available at: https://www.fn-test.com/product/eh4171/ (accessed April
2024).
14. Enzyme-linked immunosorbent assay kit for anti-desmoglein 3
antibody (Anti-DSG3). Available at: https://www.cloud-clone.com/
products/SEA444Hu.html (accessed April 2024).
15. Assay Genie. Human Anti-DSG3 antibody (anti-Desmoglein-3
antibody) ELISA Kit. Available at: https://www.assaygenie.com/
human-anti-dsg3-antibody-anti-desmoglein-3-antibody-elisa-kit/ (accessed
April 2024).
16. Probst C., Schlumberger W., Stöcker W., Recke A., Schmidt E., Hashimoto
T. et al. Development of ELISA for the specific determination
of autoantibodies against envoplakin and periplakin in paraneoplastic
pemphigus. Clin. Chim. Acta. 2009; 410 (1-2): 13-8. DOI: 10.1016/j.
cca.2009.08.022.
17. Keller J.J., Kittridge A.L., Debanne S.M., Korman N.J. Evaluation of
ELISA testing for BP180 and BP230 as a diagnostic modality for bullous
pemphigoid: a clinical experience. Arch. Dermatol. Res. 2016;
308 (4): 269–72.
18. Kobayashi M., Amagai M., Kuroda-Kinoshita K., Hashimoto T., Shirakata
Y., Hashimoto Koji. et al. BP180 ELISA using bacterial recombinant
NC16a protein as a diagnostic and monitoring tool for bullous
pemphigoid. J. Dermatol. Sci. 2002; 30 (3): 224-32. DOI: 10.1016/
s0923-1811(02)00109-3.
19. Sitaru C., Dähnrich C., Probst C., Komorowski L., Blӧcker I., Schmidtet
E. et al. Enzyme-linked immunosorbent assay using multimers of the
16th non-collagenous domain of the BP180 antigen for sensitive and
specific detection of pemphigoid autoantibodies. Exp. Dermatol. 2007;
16 (9): 770-7. DOI: 10.1111/j.1600-0625.2007.00592.x.
20. Tampoia M., Lattanzi V., Zucano A., Villalta D., Filotico R., Fontana
A. et al. Evaluation of a new ELISA assay for detection of BP230 autoantibodies
in bullous pemphigoid. Ann. N. Y. Acad. Sci. 2009; 1173:
15- 20. DOI: 10.1111/j.1749-6632.2009.04630.x.
21. Esmaili N., Mortazavi H., Kamyab-Hesari K., Aghazadeh N., Daneshpazhooh
M., Khani S. et al. Diagnostic accuracy of BP180 NC16a and
BP230-C3 ELISA in serum and saliva of patients with bullous pemphigoid.
Clin. Exp. Dermatol. 2015; 40 (3): 324–30.
22. Chanprapaph K., Thadanipon K. Anti-BP180 and anti-BP230 enzymelinked
immunosorbent assays for diagnosis and disease activity tracking
of bullous pemphigoid: A prospective cohort study. Asian Pacific J. Allergy
Immunol. 2021; 39 (4): 272-8. DOI: 10.12932/AP-231118-0446.
23. Horváth O., Rita Varga R., Kaneda M., Schmidt E., Thomas Ruzicka
T., Sárdy M. Diagnostic performance of the «MESACUP anti-skin
profile test» Eur. J. Dermatol. 2016; 26 (1): 56-63. DOI: 10.1684/
ejd.2015.2692.
24. Damoiseaux J., van Rijsingen M., Warnemünde N., Dähnrich C., Fechner
K., Tervaert J.W. Autoantibody detection in bullous pemphigoid:
clinical evaluation of the Europlus dermatology mosaic. J. Immunol.
Methods. 2012; 382 (1-2): 76-80. DOI: 10.1016/j.jim.2012.05.007.
25. Charneux J., Lorin J., Vitry F., Antonicelli F., Reguiai Z., Barbe C. et al.
Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent
assays in the initial diagnosis of bullous pemphigoid: a retrospective
study of 138 patients. Arch. Dermatol. 2011; 47 (3): 286-91. DOI:
10.1001/archdermatol.2011.23.
26. Koga H., Prost-Squarcioni C., Iwata H., Jonkman M.F., Ludwig R.J.,
Bieber K. Epidermolysis bullosa acquisita: The 2019 Update. Front
Med. (Lausanne) 2018; 5: 362. DOI: 10.3389/fmed.2018.00362.
27. Chen M., Chan L.S., Cai X., O’Toole E. A., Sample J. C., Woodley
D. T. Development of an ELISA for rapid detection of anti-type VII
collagen autoantibodies in epidermolysis bullosa acquisita. Journal of
Investigative Dermatology. 1997; 108 (1): 68-72. DOI: 10.1111/1523-
1747.ep12285634.
28. Holtsche M.M., an Beek N., Hashimoto T., Zenzo G.D., Zillikens D.,
Prost-Squarcioni C. et al. Diagnosis of epidermolysis bullosa acquisita:
multicentre comparison of different assays for serum anti-type vii
collagen reactivity. Acta Derm. Venereol. 2021; 101 (3): 971. DOI:
10.2340/00015555-3774.
29. Seta V., Aucouturier F., Bonnefoy J., Roux-Villet L. C., Pendaries V.,
Alexandre M. et al. Comparison of 3 type VII collagen (C7) assays
for serologic diagnosis of epidermolysis bullosa acquisita (EBA).
J. Am Acad. Dermatol. 2016; 74 (6): 1166-72. DOI: 10.1016/j.
jaad.2016.01.005.
30. Hietikko M., Hervonen K., Tuire I., Salmi T., Huhtala H., Laurila K. et al. Ex vivo culture of duodenal biopsies from patients with dermatitis
herpetiformis indicates that transglutaminase 3 antibody production
occurs in the gut. Acta Derm. Venereol. 2018; 98 (3): 366-72. DOI:
10.2340/00015555-2849.
31. Prause C., Probst C., Komorowski L., Dähnrich C., Schlumberger
W., Richter T. et al. The new anti-GAF(3X) ELISA for highly reliable
serologic diagnosis of childhood coeliac disease. Wissenschaftliche
präsentation auf dem 10th International Workshop on Autoantibodies
and Autoimmunity (IWAA), Mexiko, 2008.
32. Rose C., Dähnrich C., Probst C., Stöcker W., Schlumberger W., Zillikens
D. Anti-GAF(3X) ELISA (IgG) in combination with anti-tTGELISA
(IgA) idenifies 100% of celiac disease patients with dermatitis
herpetiformis Duhring and positive intestinal biopsy (March III). Abstract
zum 6. International Congress on Autoimmunity in Porto, Portugal,
2008.
33. Euroimmun Anti-tissue Transglutaminase ELISA (IgA) Test
instruction. Available at: https://www.intimakmur.co.id/uploads/files/
produk/ifu/20210712164420-ifu-anti-tissue-transglutaminase-elisaiga.
pdf (accessed April 2024).
34. Test instructionAnti-Tissue-Transglutaminase Orgentec Diagnostika
GmbH (Germany). Available at: https://www.orgentec.
com/en/products/alegria/autoimmune+disease+ diagnostics/
gastroenterology+diagnostics/Anti-Tissue-Transglutaminase.html (accessed
April 2024).
35. van Beek N., Dähnrich C., Johannsen N., Lemcke S., Goletz S., Hübner
F. et al. Prospective studies on the routine use of a novel multivariant
enzyme-linked immunosorbent assay for the diagnosis of autoimmune
bullous diseases. Journal of the American Academy of Dermatology.
2016; 76 (5): 889–894.e5. DOI: 10.1016/j.jaad.2016.11.002.
36. Mutasim M.D. Practice Update. Novel multivariant ELISA effective
for the diagnosis of autoimmune blistering diseases. Accessible via
Google: https://www.practiceupdate.com/content/novel-multivariantelisa-
effective-for-the-diagnosis-of-autoimmune-blistering-diseases/
48603 (accessed April 2024).
37. van Beek N., Luttmann N., Huebner F., Recke A., Karl I., Schulze F.S.
et al. Correlation of serum levels of IgE autoantibodies against BP180
with bullous pemphigoid disease activity. JAMA Dermatol. 2017;
(5391): 30–8. DOI: 10.1001/jamadermatol.2016.3357.
38. Hashimoto T., Ohzono A., Teye K., Numata S., Hiroyasu S., Tsuruta D.
et al. Detection of IgE autoantibodies to BP180 and BP230 and their
relationship to clinical features in bullous pemphigoid. Br. J. Dermatol.
2017; 77 (1): 141–51. DOI: 10.1111/bjd.15114.
39. Ishii N., Teye K., Fukuda S., Uehara R., Hachiya T., Koga H. et al.
Anti-desmocollin autoantibodies in nonclassical pemphigus. Br. J.
Dermatol. 2015; 173 (1): 59–68. DOI: 10.1111/bjd.13711.
40. Groth S., Recke A., Vafia K., Ludwig R. J., Hashimoto T., Zillikens
D. et al. Development of a simple enzyme-linked immunosorbent assay
for the detection of autoantibodies in anti-p200 pemphigoid. Br.
J. Dermatol. 2011; 164 (1): 76–82. DOI: 10.1111/j.1365-2133.2010.
10056.x.
41. Csorba K., Schmidt S., Florea F., Ishii N., Hashimoto T., Hertl M. et
al. Development of an ELISA for sensitive and specific detection of
IgA autoantibodies against BP180 in pemphigoid diseases. Orphanet.
J. Rare Dis. 2011; 6: 31. DOI: 10.1186/1750-1172-6-31.
42. Izumi K., Nishie W., Mai Y., Wada M., Natsuga K., Ujiie H. et al.
Autoantibody profile differentiates between inflammatory and noninflammatory
bullous pemphigoid. J. Invest. Dermatol. 2016; 136 (11):
2201–10. DOI: 10.1016/j.jid.2016.06.622.
43. Yasukochi A., Teye K., Ishii N., Hashimoto T. Clinical and immunological
studies of 332 Japanese patients tentatively diagnosed as
anti-BP180-type mucous membrane pemphigoid: a novel BP180 Cterminal
domain enzyme-linked immunosorbent assay. Acta Derm. Venereol.
2016; 96: 762–7. DOI: 10.2340/00015555-2407.
44. Bernard P., Antonicelli F., Bedane C., JolyP., Le Roux-Villet C.,
Duvert-Lehembre S. et al. Prevalence and clinical significance of
anti-laminin 332 autoantibodies detected by a novel enzyme-linked
immunosorbent assay in mucous membrane pemphigoid. JAMA
Dermatol. 2013; 149 (5): 533–40. DOI: 10.1001/jamadermatol.
2013.1434.
45. Svirshcevskaya E.V., Matushevskaya E.V., Dzutseva I.R., Lysenko A.A.
Development of an immunoenzyme test system based on yeast recombinant
desmoglein 3 for serodiagnosis of vesicular vesicular vulgar disease.
Vestnik Dermatologii i Venerologii. 2005; (3): 4-10. (in Russian)
46. Matushevskaya E.V., Svirshcevskaya E.V., Dzutseva I.R., Togoeva
L.T., Lapshina T.P. Serum antidesmoglein-3 antibodies in patients with
pemphigus before and after therapy. Vestnik Dermatologii i Venerologii.
2005; (6): 12-6. (in Russian)
47. Kubanov A.A., Deryabin D.G., Shpilevay M.V., A.E. Karamova A.E.,
Nikonorov A.A., Larina E. N. et al. Analysis of the specificity of autoreactive
antibodies to individual fragments of the extracellular domain
of desmoglein 3 in patients with pemphigus vulgaris. Bulletin of Experimental
Biology and Medicine. 2021; 171 (4): 475-9. DOI: 10.1007/
s10517-021-05254-9.